SK biopharmaceuticals

Seongnam-si, South Korea Founded: 1993 • Age: 33 yrs
Therapeutics for central nervous system disorders are developed.
Request Access

About SK biopharmaceuticals

SK biopharmaceuticals is a company based in Seongnam-si (South Korea) founded in 1993.. The company has 265 employees as of December 31, 2024. SK biopharmaceuticals operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Sana Biotechnology, Kriya Therapeutics and PureTech Health, among others.

  • Headquarter Seongnam-si, South Korea
  • Employees 265 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Sk Biopharmaceuticals Co., Ltd.
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $371.31 M (USD)
    54.3
    as on Dec 31, 2024
  • Net Profit
    $163.24 M (USD)
    832.18
    as on Dec 31, 2024
  • EBITDA
    $77.12 M (USD)
    599.25
    as on Dec 31, 2024
  • Latest Funding Round
  • Investors
  • Employee Count
    265

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of SK biopharmaceuticals

SK biopharmaceuticals is a publicly listed company on the KRX with ticker symbol 326030 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: KRX · Ticker: 326030 . Sector: Health technology · South Korea

Funding Insights of SK biopharmaceuticals

  • Total Funding
  • Total Rounds 1
  • Last Round
  • First Round
  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2012 Amount Unspecified - SK biopharmaceuticals Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in SK biopharmaceuticals

SK biopharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include KDDF. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Specializes in R&D for manufacturing therapeutic drugs.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by SK biopharmaceuticals

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - SK biopharmaceuticals

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Sk Biopharmaceuticals Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of SK biopharmaceuticals

SK biopharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Sana Biotechnology, Kriya Therapeutics and PureTech Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Drugs for CNS disorders are developed and advanced.
domain founded_year HQ Location
Genetically engineered cell therapies are developed for multiple disorders.
domain founded_year HQ Location
Developer of therapeutic solutions for the treatment of diabetes
domain founded_year HQ Location
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
domain founded_year HQ Location
Therapies for neurological and neuropsychiatric diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Sk Biopharmaceuticals

Frequently Asked Questions about SK biopharmaceuticals

When was SK biopharmaceuticals founded?

SK biopharmaceuticals was founded in 1993 and raised its 1st funding round 19 years after it was founded.

Where is SK biopharmaceuticals located?

SK biopharmaceuticals is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.

Who is the current CEO of SK biopharmaceuticals?

Jeong Woo Cho is the current CEO of SK biopharmaceuticals.

How many employees does SK biopharmaceuticals have?

As of Dec 31, 2024, the latest employee count at SK biopharmaceuticals is 265.

What is the annual revenue of SK biopharmaceuticals?

Annual revenue of SK biopharmaceuticals is $371.31M as on Dec 31, 2024.

What does SK biopharmaceuticals do?

Founded in 1993, SK biopharmaceuticals is based in Seongnam-si, South Korea, and operates in the pharmaceutical sector. Focus is placed on developing drugs for central nervous system disorders and anticancer applications. Key products include cenobamate for epilepsy, carisbamate for Lennox-Gastaut syndrome, and relenopride for rare neurological disorders. Operations emphasize research and therapeutic innovation in these fields.

Who are the top competitors of SK biopharmaceuticals?

SK biopharmaceuticals's top competitors include Jazz Pharmaceuticals, Neurocrine and Biohaven Pharmaceutical.

Is SK biopharmaceuticals publicly traded?

Yes, SK biopharmaceuticals is publicly traded on KRX under the ticker symbol 326030.

Who are SK biopharmaceuticals's investors?

SK biopharmaceuticals has 1 investor. Key investors include KDDF.

What is SK biopharmaceuticals's ticker symbol?

The ticker symbol of SK biopharmaceuticals is 326030 on KRX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available